US moves to block Purdue Pharma opioid settlement

The US government is seeking to block a settlement with Purdue Pharma that would prevent further lawsuits against its founders
The US government is seeking to block a settlement with Purdue Pharma that would prevent further lawsuits against its founders.

The US Justice Department has challenged a plan that would dissolve Purdue Pharma, manufacturer of the OxyContin drug that has been blamed for the country's opioid crisis, while shielding its founders from lawsuits.

The government wants the settlement, which was approved this month by a federal judge, to be put on hold while prosecutors challenge it in a federal appeals court.

Under the deal, the Sackler families that founded and profited from the company would have to pay $4.5 billion, but they could not be taken to court again over the drug.

In a court filing released Wednesday, Justice Department Trustee William Harrington argues the deal falls short of providing accountability for the nationwide addiction crisis that caused more than 500,000 overdose deaths in the United States over the past 20 years.

The agreement "harms both the public and countless individuals by extinguishing the rights that opioid victims hold against possibly thousands of Sackler Family members and associated parties."

If the settlement is allowed to proceed, there will be no "full accounting" of these individuals and groups' roles in the "opioid disaster," the government argues.

The attorneys general of Washington, Maryland, Oregon and Connecticut also have objected to the deal, though other states support it.

Facing an avalanche of litigation, Purdue last year pled guilty to three criminal charges over its aggressive drive to push sales of OxyContin, a highly addictive prescription painkiller.

Under the terms of the deal, the company will be sold by 2024 to be replaced by a new entity managed by a trust, and its involvement in selling opioid products will be restricted.

Purdue also will be required to create a repository for tens of millions of documents detailing its sales and marketing practices.

The Sacklers have welcomed the deal, saying it avoids litigation that could take years to resolve, though detractors including Washington State Attorney General Bob Ferguson have argued it lets the families "off the hook."

Like many American billionaires, the Sacklers have made donations to prestigious institutions such as the Met Museum in New York. Many of the institutions now ban their donations.

The family's fortune diminished amid the crisis, but was still estimated at around $10.8 billion late last year, according to Forbes, which said much of that wealth came from Purdue.

© 2021 AFP

Citation: US moves to block Purdue Pharma opioid settlement (2021, September 16) retrieved 4 December 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

US judge approves deal dissolving Purdue Pharma in opioid saga


Feedback to editors